Meta-Analysis Finds Comparable Outcomes With TNF Inhibitor Cycling or Mechanism Switching in Psoriatic Arthritis
Key Clinical Summary
- A systematic review and meta-analysis of 5 observational studies involving 2300 patients with psoriatic arthritis (PsA) found no significant differences between tumor necrosis factor inhibitor (TNFi) cycling and switching to a biologic with a different mechanism of action after TNFi discontinuation.
- Clinical response, treatment retention at 12 and 24 months, and adverse event rates were comparable between treatment strategies.
- The findings suggest that treatment selection after TNFi failure may be individualized according to patient characteristics, prior treatment response, and patient preferences rather than expectations of superior efficacy.
Patients with psoriatic arthritis (PsA) who discontinue an initial tumor necrosis factor inhibitor (TNFi) appear to achieve similar clinical outcomes whether they cycle to another TNFi or switch to a biologic disease-modifying antirheumatic drug (bDMARD) with a different mechanism of action, according to a systematic review and meta-analysis published in Rheumatology (Oxford).
Study Findings
Tumor necrosis factor inhibitors remain the most widely used first-line biologic therapy for moderate-to-severe PsA because of their established efficacy, long-term clinical experience, and relatively lower cost. However, clinicians frequently face uncertainty regarding the optimal next treatment after an initial TNFi fails because of inadequate response or loss of effectiveness.
To address this question, investigators performed a systematic review and meta-analysis of randomized and observational studies comparing 2 treatment strategies following TNFi discontinuation: cycling to another TNFi or switching to a biologic with a different mechanism of action.
Five observational studies comprising 2300 patients met the inclusion criteria. Among these, 1517 patients (66.0%) received a second TNFi, while 783 patients (34.0%) switched to an alternative biologic class. Disease duration before initiation of the second biologic ranged from 3.7 to 12 years. Across studies, the most common reason for discontinuing the initial TNFi was lack of efficacy, including both primary nonresponse and secondary loss of response.
The pooled analysis found no statistically significant differences between treatment approaches for any of the primary outcomes. The pooled risk ratio (RR) for lack of treatment response was 0.99 (95% CI, 0.70-1.41). Likewise, treatment retention at 12 months (RR, 0.91; 95% CI, 0.75-1.10) and 24 months (RR, 0.96; 95% CI, 0.53-1.75) did not differ significantly between strategies. Safety outcomes were also comparable, with no significant difference in adverse events (RR, 0.94; 95% CI, 0.38-2.34).
Clinical Implications
The findings suggest that neither TNFi cycling nor mechanism switching demonstrates a clear advantage following failure of an initial TNFi in patients with PsA. Similar rates of clinical response, long-term treatment persistence, and adverse events indicate that both approaches remain reasonable therapeutic options.
For clinicians, these results support a personalized treatment strategy after TNFi discontinuation. Factors such as the reason for TNFi failure, disease manifestations, comorbid conditions, prior medication history, route of administration, patient preferences, and medication access may appropriately guide therapeutic decisions when comparative efficacy appears similar.
Because the analysis included observational studies rather than randomized controlled trials, the authors note that additional high-quality comparative research is needed to better define optimal sequencing of biologic therapies in PsA.
Expert Commentary
The investigators concluded that “following TNFi failure, cycling and swapping strategies show comparable retention and safety.” They further stated that “treatment choice may be guided by clinical characteristics and patient preference rather than clear differences in overall effectiveness.” These conclusions support individualized treatment decisions when selecting subsequent biologic therapy after discontinuation of an initial TNFi. Until more robust comparative data become available, treatment selection should remain individualized, balancing patient characteristics, therapeutic goals, and shared decision-making.
Reference
Tomo ATJ, Ratan P, Gonçalves LS, et al. Cycling versus swapping strategies for treatment of psoriatic arthritis after primary tumour necrosis factor inhibitors failure: A systematic review and meta-analysis. Rheumatology (Oxford). 2026;65(6):keag281. doi:10.1093/rheumatology/keag281
